Science
CME credits: 0.50 Valid until: 11-12-2021 Claim your CME credit at https://reachmd.com/programs/cme/improving-pump-function-in-heart-failure-with-reduced-ejection-fraction/12036/ A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction (HFrEF) is the initial decrease in systolic function. The purpose of inotropic interventions in HF is to increase the muscular contractile force of the myocardium. Current intravenous inotropes and previously investigated oral positive inotropic drugs exert their effect by modulating calcium signaling in the myocardium. Results from clinical trials with these agents have indicated poor long-term outcomes and signals of increased mortality. Emerging pharmacological agents that improve contraction by novel mechanisms of action may be able to improve clinical outcomes for patients with chronic HFrEF. In this educational initiative, a panel of HF experts will 1) discuss the concept of inotropy, describe previous attempts to improve clinical outcomes with inotropes, and summarize their current use 2) explain new calcium-independent approaches to improve myocardial contractility, and 3) interpret recently published evidence and potential implications for clinical practice.